360 related articles for article (PubMed ID: 15769863)
1. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
[TBL] [Abstract][Full Text] [Related]
2. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7.
DaCosta Byfield S; Major C; Laping NJ; Roberts AB
Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orally active transforming growth factor-beta type I receptor inhibitor.
Gellibert F; de Gouville AC; Woolven J; Mathews N; Nguyen VL; Bertho-Ruault C; Patikis A; Grygielko ET; Laping NJ; Huet S
J Med Chem; 2006 Apr; 49(7):2210-21. PubMed ID: 16570917
[TBL] [Abstract][Full Text] [Related]
4. SM16, an orally active TGF-beta type I receptor inhibitor prevents myofibroblast induction and vascular fibrosis in the rat carotid injury model.
Fu K; Corbley MJ; Sun L; Friedman JE; Shan F; Papadatos JL; Costa D; Lutterodt F; Sweigard H; Bowes S; Choi M; Boriack-Sjodin PA; Arduini RM; Sun D; Newman MN; Zhang X; Mead JN; Chuaqui CE; Cheung HK; Zhang X; Cornebise M; Carter MB; Josiah S; Singh J; Lee WC; Gill A; Ling LE
Arterioscler Thromb Vasc Biol; 2008 Apr; 28(4):665-71. PubMed ID: 18202322
[TBL] [Abstract][Full Text] [Related]
5. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy.
Moon JA; Kim HT; Cho IS; Sheen YY; Kim DK
Kidney Int; 2006 Oct; 70(7):1234-43. PubMed ID: 16929250
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of activin receptor-like kinase 5 attenuates bleomycin-induced pulmonary fibrosis.
Higashiyama H; Yoshimoto D; Kaise T; Matsubara S; Fujiwara M; Kikkawa H; Asano S; Kinoshita M
Exp Mol Pathol; 2007 Aug; 83(1):39-46. PubMed ID: 17274978
[TBL] [Abstract][Full Text] [Related]
7. Growth state-dependent regulation of plasminogen activator inhibitor type-1 gene expression during epithelial cell stimulation by serum and transforming growth factor-beta1.
Boehm JR; Kutz SM; Sage EH; Staiano-Coico L; Higgins PJ
J Cell Physiol; 1999 Oct; 181(1):96-106. PubMed ID: 10457357
[TBL] [Abstract][Full Text] [Related]
8. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
Park CY; Kim DK; Sheen YY
Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542.
Laping NJ; Grygielko E; Mathur A; Butter S; Bomberger J; Tweed C; Martin W; Fornwald J; Lehr R; Harling J; Gaster L; Callahan JF; Olson BA
Mol Pharmacol; 2002 Jul; 62(1):58-64. PubMed ID: 12065755
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-I-related regulation of procollagen I (alpha1 and alpha2) by antitransforming growth factor-beta1 treatment during radiation-impaired wound healing.
Schultze-Mosgau S; Kopp J; Thorwarth M; Rödel F; Melnychenko I; Grabenbauer GG; Amann K; Wehrhan F
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):280-8. PubMed ID: 16377416
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta 1-induced PAI-1 expression is E box/USF-dependent and requires EGFR signaling.
Kutz SM; Higgins CE; Samarakoon R; Higgins SP; Allen RR; Qi L; Higgins PJ
Exp Cell Res; 2006 Apr; 312(7):1093-105. PubMed ID: 16457817
[TBL] [Abstract][Full Text] [Related]
12. Safflower extract: a novel renal fibrosis antagonist that functions by suppressing autocrine TGF-beta.
Yang YL; Chang SY; Teng HC; Liu YS; Lee TC; Chuang LY; Guh JY; Chang FR; Liao TN; Huang JS; Yeh JH; Chang WT; Hung MY; Wang CJ; Chiang TA; Hung CY; Hung TJ
J Cell Biochem; 2008 Jun; 104(3):908-19. PubMed ID: 18189272
[TBL] [Abstract][Full Text] [Related]
13. Radiation and transforming growth factor-beta cooperate in transcriptional activation of the profibrotic plasminogen activator inhibitor-1 gene.
Hageman J; Eggen BJ; Rozema T; Damman K; Kampinga HH; Coppes RP
Clin Cancer Res; 2005 Aug; 11(16):5956-64. PubMed ID: 16115939
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of plasminogen activator inhibitor-1 by transforming growth factor-beta, activin A and microphthalmia-associated transcription factor.
Murakami M; Ikeda T; Saito T; Ogawa K; Nishino Y; Nakaya K; Funaba M
Cell Signal; 2006 Feb; 18(2):256-65. PubMed ID: 15961275
[TBL] [Abstract][Full Text] [Related]
15. Fuzheng Huayu recipe and vitamin E reverse renal interstitial fibrosis through counteracting TGF-beta1-induced epithelial-to-mesenchymal transition.
Wang QL; Yuan JL; Tao YY; Zhang Y; Liu P; Liu CH
J Ethnopharmacol; 2010 Feb; 127(3):631-40. PubMed ID: 20015471
[TBL] [Abstract][Full Text] [Related]
16. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes.
Seo JY; Park J; Yu MR; Kim YS; Ha H; Lee HB
Am J Nephrol; 2009; 30(6):481-90. PubMed ID: 19786738
[TBL] [Abstract][Full Text] [Related]
17. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor-beta type 1 receptor (ALK5) and Smad proteins mediate TIMP-1 and collagen synthesis in experimental intestinal fibrosis.
Medina C; Santos-Martinez MJ; Santana A; Paz-Cabrera MC; Johnston MJ; Mourelle M; Salas A; Guarner F
J Pathol; 2011 Aug; 224(4):461-72. PubMed ID: 21465486
[TBL] [Abstract][Full Text] [Related]
19. Progressive transforming growth factor beta1-induced lung fibrosis is blocked by an orally active ALK5 kinase inhibitor.
Bonniaud P; Margetts PJ; Kolb M; Schroeder JA; Kapoun AM; Damm D; Murphy A; Chakravarty S; Dugar S; Higgins L; Protter AA; Gauldie J
Am J Respir Crit Care Med; 2005 Apr; 171(8):889-98. PubMed ID: 15563636
[TBL] [Abstract][Full Text] [Related]
20. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta.
Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T
Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
